Skip to main content

Table 3 Univariate and multivariate analysis of overall survival

From: The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

  Univariate analysis Multivariate analysis
HR (95%CI) p value HR (95%CI) p value
sex 1.78(0.90–3.52) 0.09 1.30(0.62–2.73) 0.49
age (years) 0.66(0.33–1.32) 0.24   
smoking 1.45(0.71–2.89) 0.29   
T stage 0.27(0.12–0.57) 0.001 0.29(0.12–0.70) 0.006
N stage 0.53(0.26–1.06) 0.07 0.55(0.26–1.16) 0.12
EGFR mutation 1.25(0.67–2.34) 0.48   
No. mets 0.99(0.51–1.99) 0.99   
No. mets. Organs 0.27(0.09–0.77) 0.02 1.01(0.27–4.30) 0.92
lung mets 1.91(0.89–4.10) 0.09 2.0(0.72–6.99) 0.11
bone mets 0.95(0.46–1.95) 0.89   
adrenal gland mets 1.94(0.46–8.17) 0.35   
brain mets 1.68(0.84–3.36) 0.14   
LN mets 2.05(1.02–4.10) 0.04 1.80(0.82–3.96) 0.15
Osimertinib 1.07(0.31–3.71) 0.91   
LCT 1.39(0.43–4.52) 0.58 0.37(0.12–1.16) 0.09
  1. Abbreviation: LCT local consolidative therapy, No number, mets metastasis, LN lymph node